Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II oral LBH589 monotherapy in relapsed/refractory multiple myeloma
NL-OMON30969Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in multiple myeloma (MM), sponsored by Novartis. Primary endpoint: Hematologic response rate. Planned start Jun 2007; status: not yet recruiting.
02
Drugs
panobinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON30969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30969.